Abstract | BACKGROUND: METHODS AND RESULTS: In a clinical trial with minimal exclusion criteria, we randomly assigned 3002 patients to treatment with sirolimus- and probucol-eluting stents versus zotarolimus-eluting stents. The trial was designed to demonstrate noninferiority of the sirolimus- and probucol-eluting stents. The primary end point was the combined incidence of cardiac death, target-vessel-related myocardial infarction, or target-lesion revascularization at 1-year follow-up. Follow-up angiography was scheduled at 6 to 8 months. The sirolimus- and probucol-eluting stent was noninferior to the zotarolimus-eluting stent in terms of occurrence of the primary end point (13.1% versus 13.5%, respectively, P(noninferiority)=0.006; hazard ratio=0.97, 95% confidence interval, 0.78 to 1.19; P(superiority)=0.74). The incidence of definite/probable stent thrombosis was low in both groups (1.1% versus 1.2%, respectively; hazard ratio=0.91 [95% confidence interval, 0.45 to 1.84], P=0.80). With regard to angiographic efficacy, there were no differences between the sirolimus- and probucol-eluting stent and the zotarolimus-eluting stent in terms of either in-segment binary angiographic restenosis (13.3% versus 13.4% respectively; P=0.95) or in- stent late luminal loss (0.31±0.58 mm versus 0.29±0.56 mm, respectively; P=0.46). CONCLUSION: CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier NCT 00598533.
|
Authors | Steffen Massberg, Robert A Byrne, Adnan Kastrati, Stefanie Schulz, Jürgen Pache, Jörg Hausleiter, Tareq Ibrahim, Massimiliano Fusaro, Ilka Ott, Albert Schömig, Karl-Ludwig Laugwitz, Julinda Mehilli, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators |
Journal | Circulation
(Circulation)
Vol. 124
Issue 5
Pg. 624-32
(Aug 02 2011)
ISSN: 1524-4539 [Electronic] United States |
PMID | 21768546
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Immunosuppressive Agents
- Polymers
- zotarolimus
- Probucol
- Sirolimus
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
(instrumentation, methods, statistics & numerical data)
- Anticholesteremic Agents
(therapeutic use)
- Coronary Angiography
- Coronary Artery Disease
(diagnostic imaging, mortality, therapy)
- Drug-Eluting Stents
(adverse effects, statistics & numerical data)
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(mortality)
- Polymers
(adverse effects, chemistry)
- Probucol
(therapeutic use)
- Prosthesis Design
- Sirolimus
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|